PHARMACOTHERAPY REVIEW CNS STIMULANTS for treatment of ...

More documents

Recommendations

Info

1415161718192021222324252627The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering oflow-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes insaphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-62.Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes ofaggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation inthe post coronary artery bypass graft trial. Circulation 2000;102:157-65.Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk ofstroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313-21.LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis ofrandomized controlled trails. JAMA. 1999;282:2340-6.Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarctionwith pravastatin. The cholesterol and recurrent events (CARE) study. Circulation 1999;99:216-23.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive summary of the third report of the National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (adulttreatment panel III). JAMA. 2001;285:2486-97.Austin MA, Hokanson JE, Edwards KL, et al. Hypertriglyceridemia as a cardiovascular riskfactor. Am J Cardiol. 1998;81(4A):7-12.Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am JMed. 1998;105:505-62.Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): amultisource survey to evaluate the percentage of dyslipidemic patients receiving lipid loweringtherapy and achieving low density lipoprotein goals. Arch Intern Med. 2000;160:459-67.Hoerger TJ, Bula MV, Bray JW, et al. Treatment patterns and distribution of low-densitylipoprotein cholesterol levels in treatment – eligible U.S. adults. Am J Cardiol. 1998;82:61-65.McKenney JM. New cholesterol guidelines, new treatment challenges. Pharmocotherapy.2002;228:853-863.Denke MA, Grundy SM. Efficacy of low-dose cholesterol loweoirng drug therapy in men withmoderate hypercholesterolemia. Arch Intern Med. 1995;155:393-99.Gardner SF, Schneider EF, Granberry MC, et al. Combination therapy with low-dose lovastatinand niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996;16:419-23.Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three drug therapy with niacin, lovastatinand colestipol to reduce LDL cholesterol < 100 mg/dL in patients with hyperlipidemia and CAD.Am J Cardiol. 1997;80:111-15.25
2829303132333435Ballantyne CM, Andrews TC, Hsia JA, et al. Correlation of non-HDL cholesterol withapolipoprotein B: effect of 5-hydroxymethyl glutaryl coenzyme A reductase inhibitors on non-HDL cholesterol levels. Am J Cardiol. 2001;88:265-69.Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when addedsequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 2001;87:476-79.O’Keefe JH, Harris WS. Omega-3 fatty acids: time for clinical implementation? Am J Cardiol.2000;85:1239-41.deLorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors and the rate ofcardiovascular complications after myocardial infarction: final report from the Lyon diet heartstudy. Circulation. 1999;99:779-85.GISSI Prevenzione Investigators. Dietary supplements with n-3 polyunsaturated fatty acids andvitamin E after myocardial infarction: results of the GISSI prevenzione trial. Lancet.1999;354:447-55.Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasmalipids and lipoproteins in patients with combined hyperipidemia. Arterioscler Thromb.1993;13:1755-62.Kastelein JJP. Selective cholesterol absorption inhibitors: a new class of drugs for lipidmanagement. XVI international symposium on drugs affecting lipid metabolism. New York, NY.Sept 9-12.2001.Tatro DS. Drug Interaction Facts. Facts and Comparisons, St. Louis, MO. 2003 edition.Other ReferencesASHP Commission on Therapeutics. ASHP therapeutic position statement on the use of statins in theprevention of atherosclerotic vascular disease in adults. Am J Health – Syst Pharm. 2003;60:593-98.Irons BK, Snella KA, McCall K, et al. Update on the management of dyslipidemia. Am J Health – SystPharm. 2002;59:1615-25.Abramowicz M, ed. Three new drugs for hyperlipidemia. The Medical Letter. 2003 (March3);45:17-19.Abramowicz M, ed. Choice of lipid-regulating drugs. The Medical Letter. 2001(May 28);43:43-48.Wickersham R. Antihyperlipidemic agents. Drugs Facts and Comparisons. St. Louis, MO. 2003.Pasternak RC, Smith SC, Bairey CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety ofstatins. Circulation. 2002;106:1024-28.26
Page 1 and 2: PHARMACOTHERAPY REVIEWCNS STIMULANT
Page 3 and 4: D. CNS Stimulants Indicated to Trea
Page 5 and 6: Product Group Onset of Action (min)
Page 7 and 8: APPENDIX ADSM-IV-TR DIAGNOSTIC CRIT
Page 9 and 10: BIBLIOGRAPHY123456789101112American
Page 11 and 12: 252627282930Pelham WE, Greenslade K
Page 13 and 14: III.TREATMENT GUIDELINESClinical tr
Page 15 and 16: Table 3. Typical Dose-Related Reduc
Page 17 and 18: Muscle toxicity is the most serious
Page 19 and 20: Another drug, relatively new to the
Page 21 and 22: Statins (continued)Grapefruit juice
Page 23 and 24: Committee that all strengths of the
Page 25 and 26: AFCAPS/TexCAPS(The Air Force/ Texas
Page 27 and 28: 4S(Scandinavian Simvastatin Surviva
Page 29 and 30: CARE(The Cholesterol and Recurrent
Page 31 and 32: PPP(Prospective Pravastatin Pooling
Page 33 and 34: MRC/BHF Heart Protection Study• S
Page 35: BIBLIOGRAPHY12345678910111213Americ
Page 39 and 40: the American Medical Association (J
Page 41 and 42: In Table 2 of the Beer’s List (At

PHARMACOTHERAPY REVIEW CNS STIMULANTS for treatment of ...

Create successful ePaper yourself

Delete template?

Save as template?